Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Randomized Double-Blind Placebo-Controlled Cross-Over Study of TAK-831 in Schizophrenia
2017-001739-38Phase 2Unknown
- Sponsor
- Takeda
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of luvadaxistat in schizophrenia (2 arms), sponsored by Takeda. Primary endpoint: Average percentage of conditioned responses during the eyeblink conditioning (EBC) test. Status: unknown.
02
Drugs
luvadaxistat
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2017-001739-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001739-38.